Evidence map›Paper›PMID 27840641›Full record

ArticleObstetrics and gynecology international2016

Retrospective Case Reports of Anemic Pregnant Women Receiving Intravenous Ferric Carboxymaltose: Experience from a Tertiary Hospital in Spain.

Rafael Aporta Rodriguez, Mariola García Montero, Jose Pablo Lorente Aporta, Carolina Gallego Luque, Alfonso Chacón Mayor, Jose Aragón Ruiz, Virginia Torres Degayón, Claudia García Jimenez, Guadalupe Sanchez Sanchez

Open access · goldAbstract read
In one paragraph

Article in Obstetrics and gynecology international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rafael Aporta RodriguezHematology Department, Hospital Universitario de Ceuta, Ceuta, Spain.ORCID 0000-0003-4778-0393
Mariola García MonteroHematology Department, Hospital Universitario de Ceuta, Ceuta, Spain.
Jose Pablo Lorente AportaHematology Department, Hospital Universitario de Ceuta, Ceuta, Spain.
Carolina Gallego LuqueHematology Department, Hospital Universitario de Ceuta, Ceuta, Spain.
Alfonso Chacón MayorHematology Department, Hospital Universitario de Ceuta, Ceuta, Spain.
Jose Aragón RuizGynecology and Obstetrics Department, Hospital Universitario de Ceuta, Ceuta, Spain.
Virginia Torres DegayónPharmacy Department, Hospital Universitario de Ceuta, Ceuta, Spain.
Claudia García JimenezPharmacy Department, Hospital Universitario de Ceuta, Ceuta, Spain.
Guadalupe Sanchez SanchezDermatology Department, Hospital Universitario de Ceuta, Ceuta, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Iron deficiency and iron deficiency anemia during pregnancy call for safe treatment options that raise maternal hemoglobin levels and counterbalance iron demand and blood volume expansion while minimizing risks for the growing fetus. This retrospective study describes experience with intravenous ferric carboxymaltose given to pregnant women in a tertiary hospital in Spain. In a 5-year period, 95 pregnant women who had pretreatment hemoglobin <10 g/dL and at least one time of ferric carboxymaltose administration during pregnancy were included. Main outcome measures were week of pregnancy at iron administration, Hb levels before and after treatment, neonatal 5-minute Apgar scores, and birth weight. The majority received one dose of ferric carboxymaltose (1000 mg iron) during advanced pregnancy (median 31 weeks; interquartile range [IQR]: 27; 37 weeks) with minor to no adverse outcomes. Overall, median Hb increased from 8.5 g/dL (8.1; 8.9 g/dL) before treatment to 11.0 g/dL (9.9; 11.7 g/dL) after treatment. Normal Apgar scores were observed in all 97 infants (median birth weights 3560 g, 3270, and 3798 g). Four women received ferric carboxymaltose in the first trimester and twenty-eight during the second trimester without adverse outcomes for mother or child. These cases add to the evidence that ferric carboxymaltose administration during pregnancy is effective and safe.

Identifiers

PMID27840641
PMCPMC5093275
OpenAlexW2539416331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.